Trials / Not Yet Recruiting
Not Yet RecruitingNCT06837571
Methadone Dose Monitoring With a Remote Medication Monitor
Assessment of Methadone Dose Taken
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 30 (estimated)
- Sponsor
- Cari Health Inc. · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Proof of concept: Pilot Study A Pilot, proof of concept, observational study with a long-term goal to develop a minimally invasive wearable Remote Medication Monitor (RMM) that provides continuous, real-time data on methadone levels in interstitial fluid (ISF). An RMM could be used as a medication adherence monitor and would allow for the physician, counselor, patient, or family member to remotely verify that a physician-prescribed dose has been taken.
Detailed description
The investigator will conduct a non-randomized, non-blinded, feasibility study at a single center in the United States. The study will include up to 20 subjects of an equal number of male and female adults (ages 18-70) who have a prescription for methadone. In Aim 1, the investigators will determine if an RMM can continuously assess the status of taking a prescribed dose of methadone over time, by inserting the dermal ISF sensing elements into the subjects' abdominal skin. Biosample collections (i.e., ISF, blood) and pharmacokinetic monitoring will occur over a 6-hour period. By completing this aim, the investigator will determine if a physician is able to recognize the pharmacokinetic profile of a taken dose of methadone. The physician will see a dosing curve display generated from dermal ISF dialysis fluid sampling using an external fiberoptic sensor system that is worn continuously on the abdomen similar to continuous glucose monitors.
Conditions
- Methadone Toxicity
- Methadone Overdose
- Pain, Chronic
- Drug Metabolism, Poor, CYP2D6-Related
- Metabolism Medication Toxicity
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Measurement of Methadone in the Interstitial Fluid (ISF) before and after prescribed dose taken ex vivo | Measurement of Methadone and its metabolites in interstitial fluid with Liquid Chromatography - Mass Spectroscopy (LC-MS) and Aptamer based Assay |
| DRUG | Measurement of Methadone in the Interstitial Fluid before and after prescribed dose taken in vivo | Measurement of Methadone and its metabolites in ISF with LC-MS and RMM |
| DEVICE | ISF Extraction Device 2 | Up to 15 minute periods of continuous ISF collection for analysis |
Timeline
- Start date
- 2025-04-26
- Primary completion
- 2025-05-01
- Completion
- 2025-06-01
- First posted
- 2025-02-20
- Last updated
- 2025-02-20
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06837571. Inclusion in this directory is not an endorsement.